AI in Medicine: Transforming Healthcare from Bedside to Bench
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease,such as a history of heart attack,stroke,or peripheral artery disease.
- the average participant in the trial had a BMI of 38.0 kg/m2 and a history of cardiovascular disease.
ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study,involving over 17,600 participants,showed a statistically notable,though relatively small,increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Who is Affected? Understanding the Patient Population
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease,such as a history of heart attack,stroke,or peripheral artery disease. It’s crucial to understand this is *not* a blanket warning for everyone using Ozempic. The increased risk was observed in this specific, higher-risk group.Individuals using semaglutide for type 2 diabetes management, or those with obesity but no prior cardiovascular events, may not face the same elevated risk.
the average participant in the trial had a BMI of 38.0 kg/m2 and a history of cardiovascular disease. Approximately 50% had a prior heart attack, and 38% had peripheral artery disease. The average follow-up period was 3.7 years, providing a substantial timeframe for observing cardiovascular events.
The Data: A detailed Breakdown of the Findings
The study reported a hazard ratio of 1.25 (95% confidence interval,1.07 to 1.46) for the composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. This means the risk of these events was 25% higher in the semaglutide group compared to the placebo group. While statistically significant, it’s crucial to note this translates to an absolute risk increase of 4.8 events per 1000 person-years.
| Event | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.6% | 1.42 (1.04-1.93) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.88-2.01) |
| Nonfatal Stroke | 3.1% | 1.9% | 1.68 (1.08-2.62) |
| Unstable Angina | 3.2% | 2.2% | 1.44 (0.96-2.15) |